Influenza B viruses have been represented in human populations in recent years by two divergent strains, B/Victoria/2/87-like and B/Yamagata/16/88- like viruses.Drift in the B/Yamagata-like viruses has been identified by a panel of ferret antisera during the past year and has raised the question of need for further alterations in vaccine composition.In order to determine human responses to new B/Yamagata-like variants, sera from 23 children and 30 adults who were immunized with vaccines containing the antigens of influenza virus B/Yamagata/16/88 were tested.Against B/Hong Kong/22/89 (an immunologically distinguishable variant of B/Yamagata), post-immunization geometric mean titers (GMT) of neu-tralizing antibodies were only approximately half those against the vaccine virus (reciprocal GMT = 344 for B/Yamagata vs. 157 for B/Hong Kong). Among the subset of children who were immunologically unprimed the disparity was more marked (GMT = 473 for B/Yamagata vs. 141 for B/Hong Kong). Against a panel of variants of B/Yamagata-like viruses that have drifted even further immunologically than B/Hong Kong (Panama/45/90, Bangkok/163/90, Illinois 2005, and Texas VC-1 1037), adult postimmunization sera tested by hemagglutination inhibition (with detergent split virus as antigen) showed no difference in GMT (218 for B/Yamagata, 218 for B/Panama, 218 for B/Illinois, 230 for B/Texas, and 179 for B/Bangkok). These results suggest that adults would be adequately protected against the newly drifted influenza B strains related to B/Yamagata, but that children, particularly those with little or no previous exposure to influenza B antigens, might be suboptimal for protection against infection. The data suggest that vaccine strategies for adults may be inadequate for children.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BF002003-03
Application #
3804805
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost